Portfolio company
Medincell
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Medincell develops long-acting injectable medicines for pharmaceutical and veterinary partners to improve patient adherence across multiple therapeutic areas.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Optimeos Life Sciences
This company develops nanoparticle drug delivery systems and long-acting injectables for pharmaceutical partners to enable targeted intracellular delivery of genetic medicines and proteins.
AmacaThera
The company develops injectable hydrogel drug delivery platforms for pharmaceutical partners to provide sustained post-surgical pain management and localised therapeutic release.
I2 Therapeutics
This company develops oral drug delivery formulations and long-acting therapies for metabolic and inflammatory diseases to improve patient adherence and treatment efficacy.
PetMedix
PetMedix develops species-specific monoclonal antibody therapeutics for companion animals to treat chronic and terminal diseases in dogs and cats.
InkVivo
The company develops polymer-based drug delivery systems for pharmaceutical and nutraceutical industries to enhance therapeutic adherence and efficacy.
ALRISE Biosystems
This company develops micro-encapsulated drug delivery systems and long-acting injectable formulations for pharmaceutical industry clients.
Drug Delivery
This company develops ingestible technology for drug delivery and health monitoring to serve patients and healthcare providers.
Eyconis
The company develops long-acting ophthalmic medicines for patients with retinal diseases such as wet age-related macular degeneration.
